Exploring miRNAs' Based Modeling Approach for Predicting PIRA in Multiple Sclerosis: A Comprehensive Analysis

Tommaso Gosetti di Sturmeck1, Leonardo Malimpensa2, Gina Ferrazzano3

  • 1European Brain Research Institute (EBRI) Rita Levi-Montalcini, 00161 Rome, Italy.

Insights

Biomarkers in microRNA profiles can predict multiple sclerosis progression independent of relapse activity. This aids in personalizing treatment strategies for patients with relapsing-remitting multiple sclerosis.

Area of Science:

  • Neuroimmunology
  • Biomarker Discovery
  • Genomics

Background:

  • Multiple sclerosis (MS) pathophysiology involves inflammation and neurodegeneration.
  • Disease Modifying Therapies (DMTs) reduce relapses but not all disability progression.
  • Progression Independent of Relapse Activity (PIRA) significantly impacts long-term disability.

Purpose of the Study:

  • Identify microRNA (miRNA) biomarkers to predict PIRA in relapsing-remitting MS (RRMS).
  • Develop models for stratifying patients based on disease trajectory.
  • Enhance personalized treatment strategies for early MS stages.

Main Methods:

  • Analyzed miRNA profiles from peripheral blood mononuclear cells of 25 RRMS patients before and after high-efficacy DMTs.
  • Utilized Agilent microarrays for miRNA profiling.
  • Employed multivariate logistic and linear models with randomization tests for analysis.

Main Results:

  • Selected a subset of miRNAs correlated with PIRA and Expanded Disability Status Scale (EDSS) changes.
  • Developed a robust logistic model predicting PIRA status with high accuracy (AUC = 0.971).
  • Built a multilinear model using four miRNA predictors to describe EDSS changes.

Conclusions:

  • Multivariate modeling of miRNA expression shows promise for predicting MS disability progression.
  • Baseline miRNA profiles can stratify patients regarding PIRA risk.
  • These findings support the development of personalized therapeutic approaches for MS.